1. Dalton JT, Geuns ER, and Au JLS. High-Performance Liquid Chromatographic Determination of Mitomycin C in Rat and Human Plasma and Urine. Journal of Chromatography (Biomedical Applications), 495: 330-337, 1989.
2. Wientjes MG, Dalton JT, Badalament RA, Dasani BM, Drago JR, and Au JLS. A Method to Study Drug Concentration-Depth Profiles in Tissues:Mitomycin C in Dog Bladder Wall. Pharmaceutical Research, 8:168-173, 1991.
3. Au JLS, Dalton JT, and Wientjes MG. Evidence of Significant Absorption of Sodium Salicylate from Urinary Bladder of Rats. Journal of Pharmacology and Experimental Therapeutics, 258: 357-364, 1991.
4. Wientjes MG, Dalton JT, Badalament RA, Drago JR, and Au JLS. Bladder Wall Penetration of Intravesical Mitomycin C in Dogs. Cancer Research, 51: 4347-4354, 1991.
5. Dalton JT, Au JLS, Wientjes MG, and Badalament RA. Pharmacokinetics of Mitomycin C in Patients Undergoing Intravesical Therapy for Superficial Bladder Cancer. Cancer Research, 51: 5144-5152, 1991.
6. Dalton JT, Harrington MD, and Au JLS. Evidence of Significant Absorption of Antipyrine from Urinary Bladder of Rats. Journal of Pharmacology and Experimental Therapeutics, 260: 608-613, 1992.
7. Dalton JT and Au JLS. Specificity of Human Placental 5'-Nucleotidase: No Metabolism of 2',3'-dideoxyinosine. Journal of Drug Metabolism and Disposition, 21:544-546, 1993.
8. Yeh TK, Dalton JT, and Au JLS. High-Performance Liquid Chromatographic Determination of Pentamidine in Plasma. Journal of Chromatography (Biomedical Applications), 622: 255-61, 1994.
9. Dalton JT and Au JLS. Effect of Bladder Resorption on Pharmacokinetic Data Analysis. Journal of Pharmacokinetics and Biopharmaceutics, 22:183-205, 1994.
10. Miller DD, Zhang X, Dalton JT, Yao XT, Shukla P, and Hsu FL. Synthesis and Biological Activity of a Series of Conformationally Restricted Analogs 4-Substituted Imidazoles as a2-Adrenergic Agonists. U.S. Army Chem. Res., Devel. and Engin. Ctr, Science on Chemical Defense Research, 1995.
11. Mukherjee A, Kirkovsky L, Yao XT, Yates CR, and Dalton JT. Enantioselective Binding of Casodex to the Androgen Receptor. Xenobiotica 26(2):117-122, 1996.
12. Han G, Israel M, Seshardi R, Dalton JT, and Sweatman TW. Pharmacology of N,N-Di(n-butyl) adriamycin-14-valerate in the Rat. Cancer Chemotherapy and Pharmacology, 37:472-478, 1996.
13. Hughes TA, Heimberg M, Wang X, Wilcox H, Hughes SM, Tolley EA, Desiderio DM, and Dalton JT. Comparative Lipoprotein Metabolism of Myristate, Palmitate, and Stearate in Normolipidemic Men. Metabolism, 45:1108-1118, 1996.
14. Donkor IO, Queener SF, and Dalton JT. Pentamidine Congeners. 4. DNA Binding Affinity and Anti-Pneumocystis Carinii Activity of Butamidine Analogues. Bioorganic and Medicinal Chemistry Letters, 6:1967-1970, 1996.
15. Zhang X, Yao XT, Dalton JT, Shams G, Lei L, Patil PN, Feller DR, Hsu FL, George C, and Miller DD. Medetomidine Analogs as a2-Adrenergic Ligands. 2. Design, Synthesis, and Biological Activity of Conformationally Restricted Napthalene Derivatives of Medetomidine. Journal of Medicinal Chemistry, 39(15):3001-3013, 1996.
16. Zhang X, De Los Angeles JE, He MY, Dalton JT, Shams G, Lei L, Patil PN, Feller DR, Miller DD, and Hsu FL. Medetomidine Analogs as a2-Adrenergic Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with a2-Adrenoceptors Involving a "Methyl Pocket". Journal of Medicinal Chemistry, 40(19):3014-3024, 1997.
17. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD. Discovery of Nonsteroidal Androgens. Biochemical and Biophysical Research Communications, 244(1):1-4, 1998.
18. Kidd R, Blaisdell J, Straughn A, Meyer MC, Goldstein J, and Dalton JT. Pharmacokinetics of Phenytoin, Glipizide and Nifedipine in a Homozygous CYP2C9-Leu 359 Individual. Pharmacogenetics, 9:71-80, 1999.
19. Dalton JT, Golub AL, Zhou D, Mukherjee A, Young D and Meyer MC. Pharmacokinetics of Aminolevulinic Acid after Intravesical Dosing to Dogs. Pharmaceutical Research, 16(2):288-295, 1999.
20. Mukherjee A, Kirkovsky LI, Zhu Z, Kimura Y, Miller DD, and Dalton JT. Affinity Labeling of the Androgen Receptor with Nonsteroidal Chemoaffinity Ligands. Biochemical Pharmacology, 58: 1259-1267, 1999.
21. Dalton JT, Golub AL, Yao XT, Young D, and Meyer MC. Pharmacokinetics of Aminolevulinic Acid after Oral and Intravenous Dosing in Dogs. Drug Metabolism and Disposition, 27 (4):432-435, 1999.
22. Hovinga CA, Chicella MF, Rose DF, Eades SK, Dalton JT, and Phelps SJ. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Annals of Pharmacotherapy, 33(5):579-84, 1999.
23. Zhou D, Lu Y, Steiner MS, and Dalton JT. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Antimicrobial Agents and Chemotherapy, 44(10):2659-2663, 2000.
24. Brimer C, Dalton JT, Zhu Z, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, and Schuetz EG. Creation of Polarized Cells Co-Expressing CYP3A4, NADPH Ctyochrome P450 Reductase and MDR1/P-glycoprotein. Pharmaceutical Research, 17(7): 803-810, 2000.
25. Kirkovsky L, Mukherjee A, Yin D, Dalton JT, and Miller DD. Chiral Nonsteroidal Affinity Ligands for the Androgen Receptor. 1. Bicalutamide Analogs bearing Electrophilic Groups at the Aromatic Ring B. Journal of Medicinal Chemistry, 43: 581-590, 2000.
26. Lan LB, Dalton JT, and Schuetz EG. Mdr1 Limits CYP3A Metabolism In Vivo. Molecular Pharmacology, 58(4):863-869, 2000.
27. Yates CR, Vysokanov A, Mukherjee A, Ludden T, Tolley E, Meduri GU, and Dalton JT. Methylprednisolone population kinetics in ARDS patients: Clearance as a marker of response. Journal of Clinical Pharmacology, 41:1-10, 2001.
28. Marhefka CA, Moore II BM, Bishop TC, Kirkovsky L, Mukherjee A, Dalton JT, Miller DD. Homology Modeling Using Multiple Molecular Dynamics Simulations and Docking Studies of the Human Androgen Receptor Ligand Binding Domain Bound to Testosterone and Nonsteroidal Ligands. Journal of Medicinal Chemistry, 44: 1729-1740, 2001.
29. Zhu Z, Bulgakov O, Scott SS, and Dalton JT. Recombinant Expression And Purification Of Human Androgen Receptor In A Baculovirus System. Biochemical and Biophysical Research Communications, 284:828-835, 2001.
30. Zhu Z, Becklin RR, Desiderio DM, and Dalton JT. Identification of a Novel Phosphorylation Site of the Human Androgen Receptor by Mass Spectrometry. Biochemical and Biophysical Research Communications, 284:836-844, 2001.
31. Zhu Z, Becklin RR, Desiderio DM, and Dalton JT. Mass Spectrometric Characterization of the Human Androgen Receptor Ligand-Binding Domain Expressed in Escherichia Coli. Biochemistry, 40:10756-10763, 2001.
32. Dalton JT, Straughn AB, Dickason DA, and Grandolfi GP. Predictive Ability of Level A In Vitro/In Vivo Correlation for RingCap Controlled Release Acetaminophen Tablets. Pharmaceutical Research, 18: 1729-1734, 2001.
33. Dalton JT, Yates CR, Yin D, Straughn AB, Marcus SL, Golub AL, and Meyer MC. Clinical Pharmacokinetics of 5-Aminolevulinic Acid in Healthy Volunteers and Patients at High Risk for Recurrent Bladder Cancer. Journal of Pharmacology and Experimental Therapeutics, 301(2): 507-512, 2002.
34. Rogers TD, Gades NM, Kearbey JD, Virgous CK, and Dalton JT. Chronic Restraint Via Tail Immobilization in Mice: Effects on Corticosterone Levels and Other Physiologic Indices of Stress. Contemporary Topics in Laboratory Animal Science, 41(1):46-50, 2002.
35. He Y, Yin D, Perera MA, Kirkovsky L, Stourman N, Dalton JT, and Miller DD. Novel Nonsteroidal Ligands with High Affinity and Potent Functional Activity for the Human Androgen Receptor. European Journal of Medicinal Chemistry, 37: 619-634, 2002.
36. Yin D, He Y, Hong SS, Marhefka CA, Stourman N, Kirkovsky L, Miller DD, and Dalton JT. Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor. Molecular Pharmacology, 63:211-223, 2003.
37. Yin D, Xu H, He Y, Kirkovsky L, Miller DD, and Dalton JT. Pharmacology, Pharmacokinetics and Metabolism of Acetothiolutamide, A Novel Nonsteroidal Agonist for the Androgen Receptor. Journal of Pharmacology and Experimental Therapeutics, 304(3):1323-1333, 2003.
38. Yin D, Gao W, Kearbey JD, Xu H, Chung K, Miller DD, and Dalton JT. Pharmacodynamics of Selective Androgen Receptor Modulators. Journal of Pharmacology and Experimental Therapeutics, 304(3):1334-1340, 2003.
39. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, and Swaan PW. Structural Determinants of P-glycoprotein-Mediated Transport of Glucocorticoids. Pharmaceutical Research, 20: 1794-1803, 2003.
40. Wu Z, Gao W, Phelps M, Wu D, Miller DD, and Dalton JT. The Favorable Effects of Weak Acids on Negative-Ion Electrospray Mass Spectrometry. Analytical Chemistry, 76(3):839-847, 2004.
41. Kearbey JD, Gao W, Chung K, Miller DD, and Dalton JT. Pharmacokinetics of a Novel Selective Androgen Receptor Modulator in Rats. Xenobiotica, 34 (3): 273-280, 2004.
42. Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl CE, Dalton JT, and Miller DD. Design and Synthesis of Novel Selective Androgen Receptor Modulators: Toward in vivo Metabolic Stability. Journal of Medicinal Chemistry, 47(4):993-998, 2004.
43. Liu Y, Kim BO, Kao C, Jung C, Dalton JT, He JJ. Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa, is a negative regulator of androgen receptor (AR) transcription activation. Journal of Biological Chemistry, 279 (21): 21766-21783, 2004.
44. Bohl CE, Chang C, Mohler ML, Miller DD, Swaan PW, and Dalton JT. A Ligand-Based Approach to Identify Quantitative Structure-Activity Relationships for the Androgen Receptor. Journal of Medicinal Chemistry, 47(15):3765-3776, 2004.
45. Gao, W., Kearbey, J.D., Nair, V.A., Chung, K., Parlow, A.F., Miller, D.D., and Dalton, J.T. Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator (SARM), the 5{alpha}-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia (BPH). Endocrinology, 145(12): 5420-5428, 2004.
46. Gududuru V, Hurh E, Durgham GG, Hong SS, Sardar VM, Xu H, Dalton JT, and Miller DD. Synthesis and Biological Evaluation of Novel Cytotoxic Phospholipids for Prostate Cancer. Bioorganic and Medicinal Chemistry Letters, 14(19): 4919-4923, 2004.
47. Gududuru V, Hurh E, Dalton JT, and Miller DD. Synthesis and Antiproliferative Activity of 2-Aryl-4-Oxo-Thiazolidin-3-Yl-Amides for Prostate Cancer. Bioorganic and Medicinal Chemistry Letters, 14(21): 5289-5293, 2004.
48. Nair VA, Mustafa SM, Mohler ML, Fisher SJ, Dalton JT, and Miller DD. Synthesis of Novel Iodo Derived Bicalutamide Analogs. Tetrahedron Letters, 45: 9475-9477, 2004.
49. Chen, J., Hwang, D.J., Bohl, C.E., Miller, D.D., and Dalton, J.T. A Selective Androgen Receptor Modulator (SARM) for Hormonal Male Contraception. Journal of Pharmacology and Experimental Therapeutics, 312(2): 546-553, 2005.
50. Gududuru V, Hurh E, Dalton JT, Miller DD. Discovery of 2-Arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer. J Med Chem. 7;48(7):2584-8, 2005
51. Nair V, Mustafa SM, Mohler ML, Fisher SJ, Dalton JT, and Miller DD. Synthesis of irreversibly binding bicalutamide analogs for imaging studies. Tetrahedron Letters, 46:4821-4823, 2005.
52. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural Basis for Antagonism and Resistance of Bicalutamide in Prostate Cancer. Proc Natl Acad Sci U S A. 102(17): 6201-6206, 2005.
53. Gududuru V, Hurh E, Sullivan J, Dalton JT, and Miller DD. SAR Studies of 2-Arylthiazolidine-4-carboxylic Acid Amides: A Novel Class of Cytotoxic Agents for Prostate Cancer. Bioorganic Medicinal Chemistry Letters, 15(18): 4010-4013, 2005.
54. Chen J, Kim J, and Dalton JT. Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators. Molecular Interventions, 5(3):173-188, 2005.
55. Kim J, Wu D, Hwang DJ, Miller DD, and Dalton JT. The 4-Para-Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a Major Structural Determinant of In Vivo Disposition and Activity of Selective Androgen Receptor Modulators. Journal of Pharmacology and Experimental Therapeutics, 315(1):230-239, 2005.
56. Phelps MA, Foraker AB, Gao W, Dalton JT, Swaan PW. A novel rhodamine-riboflavin conjugate probe exhibits distinct fluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization studies. Molecular Pharmaceutics, 1(4):257-66, 2005.
57. Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, and Dalton JT. Selective Androgen Receptor Modulator (SARM) Treatment Improves Muscle Strength and Body Composition, and Prevents Bone Loss in Orchidectomized Rats. Endocrinology, 146(11):4887-4897, 2005.
58. Bohl CE, Miller DD, Chen J, Bell CE, and Dalton JT. Structural Basis for Accomodation of Nonsteroidal Ligands in the Androgen Receptor. Journal of Biological Chemistry, 280(45):37747-37754, 2005.
59. Gao W, Bohl CE, and Dalton JT. Chemistry and structural biology of androgen receptor. Chemical Reviews, 105(9):3352-70, 2005.
60. Chen J, Hwang DJ, Chung K, Bohl CE, Fisher SJ, Miller DD, Dalton JT. In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology, 146(12):5444-54, 2005.
61. Segal S, Narayanan R, Dalton JT. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opinion in Investigational Drugs. 15(4):377-87, 2006.
62. Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion in Investigational Drugs. 15(3):293-305, 2006.
63. Gao W, Johnston JS, Miller DD, Dalton JT. Inter-Species Differences in Pharmacokinetics and Metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide: The Role of N-Acetyltransferase. Drug Metabolism and Disposition, 34(2):254-260, 2006.
64. Gao W, Wu Z, Bohl CE, Yang J, Miller DD, Dalton JT. Characterization of the In vitro Metabolism of Selective Androgen Receptor Modulator (SARM) Using Human, Rat and Dog Liver Enzyme Preparations. Drug Metabolism and Disposition, 34(2):243-253, 2006.
65. Wu D, Wu Z, Yang J, Nair VA, Miller DD, Dalton JT. Pharmacokinetics and metabolism of a selective androgen receptor modulator (SARM) in rats--implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metabolism and Disposition, 34(3):483-494, 2006.
66. Yang J, Bohl CE, Nair VA, Mustafa SM, Hong SS, Miller DD, Dalton JT. Preclinical pharmacology of a nonsteroidal ligand for androgen receptor mediated imaging of prostate cancer. Journal of Pharmacology and Experimental Therapeutics, 317(1):402-408, 2006.
67. George TG, Johnsamuel J, Delfin DA, Yakovich A, Mukherjee M, Phelps MA, Dalton JT, Sackett DL, Kaiser M, Brun R, Werbovetz KA. Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorganic and Medicinal Chemistry, 14(16):5699-5710, 2006.
68. Wu D, George TG, Hurh E, Werbovetz KA, Dalton JT. Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150. Life Sciences, 79(11):1081-1093, 2006.
69. Guan N, Korukonda R, Hurh E, Schmittgen TD, Donkor IO, Dalton JT. Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. International Journal of Oncology, . 29(3):655-663.
70. Gao W, Kim J, Dalton JT. Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands. Pharmaceutical Research, 23(8):1641-1658, 2006.
71. Hwang DJ, Yang J, Xu H, Rakov IM, Mohler ML, Dalton JT, Miller DD. Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorganic and Medicinal Chemistry, .14(19):6525-6538, 2006.
72. Wu Z, Xing X, Bohl CE, Wisler JW, Dalton JT, Bell CE. Domain structure and DNA binding regions of beta protein from bacteriophage lambda. Journal of Biological Chemistry, 281(35):25205-25214., 2006.
73. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nature, Clinical Practice in Endocrinology and Metabolism, 2(3):146-159, 2006.
74. Korukonda R, Guan N, Dalton JT, Liu J, Donkor IO. Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides. Journal of Medicinal Chemistry, 49(17):5282-5290, 2006.
75. Nair VA; Mustafa SM; Mohler ML; Dalton JT; Miller DD.Synthesis of oxazolidinedione derived bicalutamide analogs . Tetrahedron Letters, 47 (23): 3953-3955, 2006.
76. Patil R, Li W, Ross CR, Kraka E, Cremer D, Mohler ML, Dalton JT, and Miller DD. Cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-N-O shiftof disubstituted phenyl ring of a bicalutamide derivative. Tetrahedron Letters, 47:3941-3944, 2006.
77. Dalton JT. Pharmacokinetics and Metabolism in Drug Design. Methods and Principles in Medicinal Chemistry. Volume 31. Second Revised Edition. By Dennis A. Smith, Han van de Waterbeemd, and Don K. Walker. Wiley-VCH, Weinheim, Germany. 2006. xix + 187 pp. 17.5 x 24.5 cm. ISBN 3527313680. Journal of Medicinal Chemistry, 14;49(25):7556-7557, 2006.
78. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 109(2):399-404, 2007.
79. Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT. Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats. Pharmaceutical Research, 24(2):328-335, 2007.
80. Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW Jr, Sun D. Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. Journal of Clinical Pharmacology, 47(2):227-37, 2007.
 [ back to top ]
|
